Regulatory
Benefit-Risk Determination
In one line
Assessment weighing probable benefits against probable risks of a device.
Definition
FDA's benefit-risk framework structures decision-making for premarket and post-market actions, considering severity and probability of harm, certainty of benefit, patient perspective, and risk tolerance.
Regulators expect benefit-risk to be argued with evidence, considering the type, magnitude, probability and duration of benefits and harms, patient tolerance for risk, uncertainty in the data and the availability of alternatives. FDA guidance describes these factors for premarket and de novo decisions. Under the EU MDR, residual risks must be acceptable when weighed against benefits, and ISO 14971 requires an overall residual risk evaluation in the risk management file.
Why it matters
Benefit-risk reasoning underpins approvability, post-market actions, and labeling decisions, especially for novel or higher-risk devices.
Common pitfalls
- •Failing to adequately document the rationale for benefit-risk determinations can lead to regulatory deficiencies.
- •Overlooking the patient’s perspective in benefit-risk assessments can result in a misaligned evaluation of device acceptability.
- •Not reassessing benefit-risk after significant Post-market Surveillance (PMS) findings can lead to continued use of unsafe devices.
- •Conflating a hazard with its associated risk can lead to an incomplete or inaccurate benefit-risk analysis.
- •Ignoring the impact of new scientific evidence on previous benefit-risk conclusions can render past assessments outdated and potentially non-compliant.
Sources
- European Commission - Medical Devices · European Commission
- IMDRF Documents · IMDRF
- RAPS Regulatory Focus · RAPS